<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Implantable cardioverter defibrillators (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e>) have shown to reduce <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality in <z:hpo ids='HP_0001635'>heart failure</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>In SCD-HeFT study, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> were programmed with a detection zone of ≥187 b.p.m </plain></SENT>
<SENT sid="2" pm="."><plain>Thus, the incidence and clinical significance of slower <z:hpo ids='HP_0004756'>ventricular tachycardias</z:hpo> (VTs) in these patients remains largely unknown, though clinically important for device selection, programming, and follow-up.METHODS AND RESULTS: We prospectively studied symptomatic <z:hpo ids='HP_0001635'>heart failure</z:hpo> patients with an indication for a primary prophylactic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> with or without concomitant resynchronization therapy according to SCD-HeFT inclusion criteria </plain></SENT>
<SENT sid="3" pm="."><plain>Devices were programmed to an additional monitor zone for slow VTs at heart rates 130-186 b.p.m </plain></SENT>
<SENT sid="4" pm="."><plain>Two hundred consecutive patients (86% male) were followed for a mean of 509 ± 308 days </plain></SENT>
<SENT sid="5" pm="."><plain>One hundred and thirty-seven patients (68.5%) were New York Heart Association class III, 75 patients (37.5%) were on cardiac resynchronization therapy, and 124 (62%) had ischaemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>We observed 473 VT episodes in 36 patients (18%) and 131 <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> episodes in 30 patients (15%) </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0004756'>Ventricular tachycardia</z:hpo> overall occurred in 40 patients (20%) </plain></SENT>
<SENT sid="8" pm="."><plain>The incidence of slow VTs was low in only 12 patients (6%) </plain></SENT>
<SENT sid="9" pm="."><plain>No patient with slow VT suffered from <z:hpo ids='HP_0001279'>syncope</z:hpo>, palpitation, or decompensation leading to hospitalization </plain></SENT>
<SENT sid="10" pm="."><plain>We did not find any reliable predictor for increased long-term risk of slow VTs.CONCLUSION: Incidence of slow VTs in a typical <z:hpo ids='HP_0001635'>heart failure</z:hpo> population with primary prophylactic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-implantation ± resynchronization therapy is very low </plain></SENT>
<SENT sid="11" pm="."><plain>Slow VTs detected in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> monitor zone remained clinically asymptomatic </plain></SENT>
<SENT sid="12" pm="."><plain>Thus, single chamber and atriobiventricular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> with a VT/<z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> zone of ≥187 b.p.m. and one burst before shock delivery might be sufficient and pragmatic for the vast majority of these patients </plain></SENT>
</text></document>